Home / Letter From The Editor / March 16, 2019

March 16, 2019

Mar 16, 2019

Metformin was approved in Canada in 1972, but did not receive approval by the FDA for type 2 diabetes until 1994, this because its sister drug phenformin happened to kill people. Although it took us 22 years to get approval we have certainly used enough in the past 25 years to make up for it.

Even with all the new whiz-bang drugs that have been developed, metformin is still the number one choice for patients newly diagnosed with type 2 diabetes. In fact, we even prescribe it for pre-diabetes, and a lower strength dose was actually part of the super pill trilogy (along with lisinopril and lovastatin) that medical researchers and public health officials wanted everyone to take, along with a multivitamin.

This week we have a compilation of research by our LECOM School of Pharmacy Pharm D. Candidate, Ghazal Blair, looking at the extra effects of metformin, especially those that affect the heart. Click here to learn why metformin is the Eveready Bunny of diabetes drugs.

ARB Update: this week the FDA gave provisional approval to a new generic manufacturer of Valsartan because of the increasing shortage of safe non-contaminated active ingredient. Hopefully they did a thorough job of vetting the manufacturer. If you want to learn what is really going on and what to do for your patients, click here.


We can make a difference!


Dave Joffe